Jan 16 (Reuters) -
* ARMO BIOSCIENCES INC SEES IPO OF UP TO 6.7 MILLION SHARES OF COMMON STOCK AND ESTIMATED IPO PRICE BETWEEN $14.00 AND $16.00 PER SHARE - SEC FILING
* ARMO BIOSCIENCES - INTENDS TO USE ABOUT $35 MILLION OF IPO PROCEEDS TO FUND DEVELOPMENT OF AM0010 FOR TREATMENT OF PDAC, INCLUDING PHASE 3 CLINICAL TRIAL
* ARMO BIOSCIENCES - INTENDS TO USE ABOUT $35 MILLION OF IPO PROCEEDS TO FUND TWO PLANNED PHASE 2B CLINICAL TRIALS IN NSCLC Source text: ( bit.ly/2FGsF7g )
 